Brain Tumor, Primary, Gliomas Benign, Meningioma, Pituitary Adenoma, Schwannoma
Conditions
Keywords
Non-malignant brain tumor, Benign brain tumor, Meningioma, Schwannoma, Pituitary adenoma, Benign glioma
Brief summary
The registry of this study was subjected to patients who were radiologically diagnosed with a non-malignant brain tumor at Seoul National University Hospital since 2001, and who have had magnetic resonance (MR) re-examination after first MR exam or will be re-examined because it was determined that immediate treatment would not be needed at the first visit to the hospital. In all MRs taken by patients, the date of imaging and the volume of the tumor are measured, and we aim to establish a natural growth history for non-malignant brain tumors.
Detailed description
Non-malignant central nervous system (CNS) tumor accounts for 70% of all primary CNS tumors, and over 300,000 patients were diagnosed with non-malignant CNS tumor per year in the United States. Not much is known about the natural history of non-malignant CNS tumors, as it is often treated immediately upon detection. However, some of them, especially small and asymptomatic non-malignant CNS tumors should not be treated immediately upon diagnosis but are observed and followed-up by repeated magnetic resonance imaging (MRI). This study aims to make a prospective cohort of non-malignant CNS tumors that do not require immediate treatment and to quantitatively analyze which factors are related to the growth of tumors. The registry of this study was subjected to patients who were radiologically diagnosed with a non-malignant brain tumor at Seoul National University Hospital since 2001, and who have had MR re-examination after first MR exam or will be re-examined because it was determined that immediate treatment would not be needed at the first visit to the hospital. Non-malignant brain tumors are defined as radiologically diagnosed neoplasms of CNS WHO grade 2 or lower among primary intracranial tumors and include meningioma, schwannoma, pituitary adenoma, and glioma suspected to be non-malignant.
Interventions
None listed
Sponsors
Seoul National University Hospital
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
for retrospective cohort * Patients with radiologically diagnosed brain neoplasm of CNS WHO grade 2 or less since 1998 * Asymptomatic at first visit to the hospital * Patients who, based on the up-to-date knowledge, did not necessarily require immediate treatment at the first hospital visit * Patients who have had two or more MRs at least 3 months apart * No previous radiotherapy or radiosurgery for the brain lesion * 18 years old or more Inclusion Criteria for prospective cohort * Patients with newly diagnosed brain neoplasm of CNS WHO grade 2 or less * Asymptomatic at first visit to the hospital * Patients who, based on the up-to-date knowledge, did not necessarily require immediate treatment at the first hospital visit and who are going to take follow-up MR exams * No previous radiotherapy or radiosurgery for the brain lesion * 18 years old or more * Patients who agree to participate by written consent
Exclusion criteria
* Patients who lost follow-up before the second MR exam * Patients requiring immediate treatment due to worsening of symptoms within 3 months of the first MR exam * Patients suspected to have other than a neoplasm at follow-up MR exams
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Tumor volume in each MRI | within 15 years after enrollment | Measured tumor volume in each MRI |
| T2 signal intensity of tumor in each MRI | within 15 years after enrollment | T2 signal intensity of tumor as a ratio to contralateral white matter |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Growth rate of tumor volume between MR exams (absolute volume) | within 15 years after enrollment | Tumor volume changed on average per year |
| Growth rate of tumor volume between MR exams (volume ratio) | within 15 years after enrollment | Percentage of tumors that change on average per year |
| Number of patients who eventually received treatment | within 15 years after enrollment | Number of patients who eventually received treatment, such as surgery, radiosurgery, radiotherapy, or hormonal therapy. |
| Pre-treatment follow-up period for patients who eventually received treatment | within 15 years after enrollment | Pre-treatment follow-up period for patients who eventually received treatment, such as surgery, radiosurgery, radiotherapy, or hormonal therapy. |
Countries
South Korea
Contacts
Primary ContactChul-Kee Park, MD PhD
Outcome results
None listed